pharmaceutical companies

Kobayashi Pharmaceutical, the Japanese company at the center of a supplement contamination scandal involving suspected deaths, is reportedly considering a buyout offer valued at more than ¥500 billion. The potential deal comes as the firm continues to face fallout from the scandal, which damaged consumer trust and hit its business hard. Market watchers are closely following how the offer could reshape the company's future.